Factors influencing neonatal therapeutic effect of anti-MRSA drugs.
OBJECTIVE
Factors influencing the neonatal therapeutic effect of anti-MRSA (methicillin-resistant Staphylococcus aureus) drugs are investigated.


METHODS
This study took place over a two-year period from April 1998 to March 2000. We calculated the non-adjusted odds ratio for each influential factor to determine the therapeutic effect of anti-MRSA drugs.


RESULTS
Significant factors for therapeutic effect were found to be platelet count, urea nitrogen, creatinine, and CRP, each measured before starting administration of anti-MRSA drugs; whether blood drug concentration was measured; and whether pneumonia or septicemia was present. There was a tendency where a better therapeutic effect was gained when the total protein and albumin values were high. We applied multivariate logistic regression analysis to these factors, and found the following independent significant factors: CRP (odds ratio (OR) = 1.582), albumin (OR = 3.079), Cre (OR -0.213), whether blood drug concentration was measured (OR = 3.767), and presence of pneumonia or septicemia (OR = 0.216). This result suggests that consideration should be given to these five important factors when treating MRSA patients.
Hayashi
H
H
Department of Pharmacy, Yokohama Seibu Hospital, The St. Marianna University School of Medicine, Yokohama, Japan.
Matsuzaki
T
T
Saito
A
A
Shimizu
M
M
Matsumoto
Y
Y
D000410:Alanine Transaminase / Q000378:metabolism; D000418:Albumins / Q000378:metabolism; D000617:Aminoglycosides / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D002097:C-Reactive Protein / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D003982:Dibekacin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D016106:Methicillin Resistance; D016017:Odds Ratio; D010976:Platelet Count; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000418:Albumins; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D003982:Dibekacin; D014640:Vancomycin; D002097:C-Reactive Protein; D003404:Creatinine; D000410:Alanine Transaminase; C031986:arbekacin